Derma Sciences (DSCI) 10-Q 9 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 08, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	DERMA SCIENCES, INC.
Entity Central Index Key	892,160
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	DSCI
Entity Common Stock, Shares Outstanding		28,269,225

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015	[1]
Current Assets
Cash and cash equivalents	$ 25,974,166	$ 15,814,205
Short-term investments	15,000,000	25,003,990
Accounts receivable, net of allowances of $3,089,492 and $667,826, respectively	10,697,668	6,307,148
Inventories	14,393,173	16,351,013
Current portion of notes receivable	938,677	0
Prepaid expenses and other current assets	1,680,343	1,406,799
Current assets of discontinued operations	577,762	7,172,095
Total current assets	69,261,789	72,055,250
Long-term equity investment	15,426,148	16,110,178
Long-term portion of notes receivable	2,086,879	0
Equipment and improvements, net of accumulated depreciation and amortization of $7,838,929 and $7,158,155, respectively	4,474,165	4,025,811
Identifiable intangible assets, net of accumulated amortization of $14,915,522 and $12,805,688, respectively	24,951,604	9,441,188
Goodwill	64,590,456	8,778,009
Other assets	103,820	99,385
Long-term assets of discontinued operations	0	5,221,689
Total assets	180,894,861	115,731,510
Current Liabilities
Accounts payable	3,194,480	3,283,581
Accrued expenses and other current liabilities	8,193,998	6,297,691
Current portion of contingent consideration	42,078,758	0
Current liabilities of discontinued operations	120,192	4,905,489
Total current liabilities	53,587,428	14,486,761
Long-term portion of contingent consideration	12,372,775	0
Long-term liabilities	498,055	1,014,378
Deferred tax liability	2,023,906	920,879
Long-term liabilities of discontinued operations	0	883,637
Total liabilities	68,482,164	17,305,655
Commitments and contingencies (Notes 3 and 13)
Stockholders’ Equity
Convertible preferred stock, $.01 par value; shares authorized 1,468,750; issued and outstanding 73,332 at September 30, 2016 and December 31, 2015 (liquidation preference of $3,222,368 at September 30, 2016)	733	733
Common stock, $.01 par value; shares authorized 50,000,000; issued and outstanding 28,269,225 at September 30, 2016 and 25,876,870 at December 31, 2015	282,692	258,769
Additional paid-in capital	248,140,518	234,943,291
Accumulated other comprehensive income	7,205,384	5,272,908
Accumulated deficit	(143,216,630)	(142,049,846)
Total stockholders’ equity	112,412,697	98,425,855
Total liabilities and stockholders’ equity	$ 180,894,861	$ 115,731,510
[1]	Reclassified for discontinued operations. See note 2.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Accounts receivable, allowances	$ 3,089,492	$ 667,826
Equipment and improvements, accumulated depreciation and amortization	7,838,929	7,158,155
Identifiable intangible assets, accumulated amortization	$ 14,915,522	$ 12,805,688
Convertible preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	1,468,750	1,468,750
Convertible preferred stock, shares issued	73,332	73,332
Convertible preferred stock, shares outstanding	73,332	73,332
Convertible preferred stock, liquidation preference	$ 3,222,368
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	28,269,225	25,876,870
Common stock, shares outstanding	28,269,225	25,876,870

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	[1]	Sep. 30, 2016	Sep. 30, 2015	[1]
Net Sales	$ 21,809,526	$ 17,787,527		$ 55,525,732	$ 51,371,639
Cost of sales	11,103,064	10,491,932		30,754,229	30,310,463
Gross Profit	10,706,462	7,295,595		24,771,503	21,061,176
Operating Expenses
Selling, general and administrative	13,694,540	12,228,883		32,726,074	38,053,638
Acquisition related	2,734,653	0		2,892,713	0
Research and development	76,274	120,386		76,274	703,511
Total operating expenses	16,505,467	12,349,269		35,695,061	38,757,149
Operating loss	(5,799,005)	(5,053,674)		(10,923,558)	(17,695,973)
Other expense, net	(230,571)	(672,259)		4,572,570	(159,533)
Loss from continuing operations before income taxes	(6,029,576)	(5,725,933)		(6,350,988)	(17,855,506)
Income tax benefit	1,456,277	1,051,892		1,394,120	755,108
Net Loss from Continuing Operations	(4,573,299)	(4,674,041)		(4,956,868)	(17,100,398)
Discontinued Operations
Loss from discontinued DSC 127 program	0	(4,851,892)		0	(13,231,893)
Income from discontinued FAD operations	261,658	591,202		1,115,583	1,558,380
Gain on sale of FAD business	3,755,205	0		3,755,205	0
Income tax provision	(835,135)	(28,071)		(1,080,704)	(84,179)
Income (Loss) from Discontinued Operations	3,181,728	(4,288,761)		3,790,084	(11,757,692)
Net Loss	$ (1,391,571)	$ (8,962,802)		$ (1,166,784)	$ (28,858,090)
Net income (loss) per common share - basic and diluted
Continuing operations	$ (0.17)	$ (0.18)		$ (0.19)	$ (0.66)
Discontinued operations	0.12	(0.17)		0.15	(0.46)
Total net loss per common share - basic and diluted	$ (0.05)	$ (0.35)		$ (0.04)	$ (1.12)
Shares used in computing net loss per common share - basic and diluted	27,241,706	25,806,549		26,343,962	25,707,314
[1]	Reclassified for discontinued operations. See note 2.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015		Sep. 30, 2016	Sep. 30, 2015
Net Loss	$ (1,391,571)	$ (8,962,802)	[1]	$ (1,166,784)	$ (28,858,090)	[1]
Other Comprehensive Income (Loss)
Foreign currency translation adjustment	29,687	(97,663)		575,471	(356,126)
Unrealized (loss) gain on equity securities, net of taxes	(219,060)	2,154,280		4,332,818	2,158,738
Less: reclassification of realized gain on equity securities included in net loss, net of taxes of $1,782,823				(2,975,813)	0
Total other comprehensive (loss) income	(189,373)	2,056,617		1,932,476	1,802,612
Comprehensive Income (Loss)	$ (1,580,944)	$ (6,906,185)		$ 765,692	$ (27,055,478)
[1]	Reclassified for discontinued operations. See note 2.

Consolidated Statements of Com6

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Unrealized gain on equity securities, net of taxes	$ (131,240)	$ 1,392,898	$ 2,595,810	$ 1,395,685
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax			$ 1,782,823	$ 0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016		Sep. 30, 2015
Operating Activities
Net loss	$ (1,166,784)		$ (28,858,090)	[1]
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of equipment and improvements	871,968		768,242
Amortization of identifiable intangible assets	2,636,176		2,238,194
Provision for bad debts	(17,415)		10,718
Allowance for sales adjustments	1,404,091		156,911
Provision for inventory obsolescence	372,326		(110,072)
Deferred rent	(63,902)		(62,240)
Stock-based compensation	1,795,418		4,086,428
Deferred income taxes	(648,413)		(1,007,843)
Change in fair value of contingent consideration	370,000		0
Gain on sale of investment	(4,740,136)		0
Loss on disposal of equipment	20,476		0
Gain on sale of FAD business	(3,755,205)		0
Changes in operating assets and liabilities:
Accounts receivable	(335,077)		(158,845)
Notes receivable	23,778		0
Inventories	3,876,456		(5,730,986)
Prepaid expenses and other assets	(45,783)		1,623,410
Accounts payable	(876,070)		(310,407)
Accrued expenses and other liabilities	(4,307,285)		45,177
Net cash used in operating activities	(4,585,381)		(27,309,403)
Investing Activities
Acquisition of a business, net of cash acquired	(13,523,738)		0
Proceeds from sale of FAD business, net of transaction costs	9,521,415		0
Proceeds of note receivable	248,000		0
Purchase of investments	(35,008,483)		(45,004,220)
Proceeds from sale of investments	52,606,631		65,996,230
Purchase of equipment and improvements	(235,128)		(1,138,895)
Net cash provided by investing activities	13,608,697		19,853,115
Financing Activities
Line of credit payment	(1,420,254)		0
Proceeds fro m issuance of common stock, net of issuance costs	2,245,867		1,991,130
Payment of withholding taxes related to employee stock-based compensation	(18,010)		(67,409)
Net cash provided by financing activities	807,603		1,923,721
Effect of exchange rate changes on cash and cash equivalents	329,042		567,235
Net increase (decrease) in cash and cash equivalents	10,159,961		(4,965,332)
Cash and cash equivalents
Beginning of period	15,814,205	[1]	19,396,845
End of period	25,974,166		14,431,513
Non-cash investing and financing activities
Issuance of common stock	9,197,875		0
Incurrence of contingent liabilities	56,761,691		0
Total	65,959,566		0
Receipt of note receivable as partial consideration in sale of FAD business	2,700,000		0
Cash paid during the period for:
Taxes	$ 445,198		$ 0
[1]	Reclassified for discontinued operations. See note 2.

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	Organization and Summary of Significant Accounting Policies Derma Sciences, Inc. and its subsidiaries (the “Company”) manufactures, markets, and distributes medical devices and placental tissue products. The Company’s operations are in two segments of the wound care marketplace: advanced wound care and traditional wound care. The Company markets its medical device products principally through direct sales representatives in the United States (“U.S.”), Canada and the United Kingdom (“U.K.”), and through independent distributors within other select international markets. The Company markets its placental tissue products principally through independent sales representatives. The Company’s U.S. distribution facilities are located in St. Louis, Missouri and Memphis, Tennessee. The Company utilizes third party distributors for distribution in Canada, Europe, Latin America, Asia and the Pacific. The Company has manufacturing facilities in Memphis, Tennessee, Toronto, Canada and Nantong, China. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. Information included in the consolidated balance sheet as of December 31, 2015 has been derived from the consolidated financial statements and footnotes thereto for the year ended December 31, 2015, included in the Annual Report on Form 10-K previously filed with the Securities and Exchange Commission. For further information refer to the Annual Report on Form 10-K for the year ended December 31, 2015. Use of Estimates Revenue Recognition Acquisitions Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of regulatory milestones and an earnout based on sales. Net Income (Loss) per Share Three and Nine Months Ended September 30, 2016 2015 Excluded dilutive shares: Convertible preferred stock 73,332 73,332 Additional stock issuable related to conversion of preferred stock 49,782 49,782 Restricted share units 343,050 674,500 Warrants - 1,755,330 Stock options 2,708,002 2,472,491 Common stock held in escrow 229,919 - Total dilutive shares 3,404,085 5,025,435 Revenue from Contracts with Customers In January 2016, the FASB issued ASU No. 2016-01, Accounting for Equity Investments and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	2. Discontinued Operations Termination of DSC 127 Program Effective November 12, 2015, the Company approved a plan to terminate its Phase 3 Aclerastide (DSC127) clinical program for diabetic foot ulcer healing. This action was based on futility determinations emanating out of the planned, pre-specified interim analyses of trial data conducted by the program’s independent Data Monitoring Committee (“DMC”). The decision to end the studies followed the recommendation by the DMC to stop the trials. Based on this recommendation, the Company initiated an orderly termination of all its existing pharmaceutical development activities, comprised of the diabetic foot ulcer healing program and two other programs utilizing the DSC127 compound for other therapeutic indications. As a result of these actions, the Company’s pharmaceutical development activities have been reported as discontinued operations in the Company’s Consolidated Financial Statements. Amounts previously reported in the Pharmaceutical Wound Care segment have been reclassified to conform to this presentation to allow for meaningful comparison of continuing operations. There were no noncash charges included in the loss from discontinued operations in the consolidated statement of operations for the three and nine months ended September 30, 2015. At September 30, 2016 and December 31, 2015, the Company had $ 65,126 4,371,010 Sale of First Aid Division (FAD) To focus its resources on advanced wound care and tissue regenerative technology, future growth, and to add capital the Company sold its First Aid Division (“FAD”) to Dukal Corporation (“Dukal”) for $ 9,670,995 2,700,000 3,755,205 Consideration Cash $ 9,670,995 Note receivable 2,700,000 Total consideration received 12,370,995 Less: Inventory 3,370,995 Fixed assets 90,309 Goodwill 4,679,684 Amortizable intangible assets 340,057 Deferred rent (14,835) Transaction costs 149,580 Net gain on sale before taxes $ 3,755,205 Discontinued operations Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Net sales $ 2,966,753 $ 4,381,140 $ 11,701,166 $ 12,852,036 Cost of sales 2,265,229 3,240,485 9,097,311 9,570,595 Gross profit 701,524 1,140,655 2,603,855 3,281,441 Selling, general and administrative 439,866 549,453 1,488,272 1,723,061 Income from discontinued operations before income taxes 261,658 591,202 1,115,583 1,558,380 Non-cash depreciation expenses of $ 17,780 22,255 50,000 56,250 September 30, 2016 December 31, 2015 Accounts receivable, net $ 556,614 $ 1,838,441 Inventory, net - 4,339,692 Prepaid expenses 21,148 993,962 Total current assets 577,762 7,172,095 Equipment and improvements, net - 103,396 Identifiable intangible assets, net - 390,057 Goodwill - 4,679,684 Other assets - 48,552 Total non-current assets - 5,221,689 Accounts payable 1,528 140,831 Accrued expenses 53,538 393,648 Total current liabilities 55,066 534,479 Deferred tax liability - 883,637 Total long-term liabilities $ - $ 883,637 Effective September 1, 2016 the Company began providing transition services to Dukal under a transition services agreement. Under the agreement, the Company shall perform corporate overhead and accounting transition services to assist in the transition of the business to Dukal through December 31, 2016. The Company shall receive monthly compensation of $ 25,000

Acquisition of BioD, LLC

Acquisition of BioD, LLC	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3. Acquisition of BioD, LLC On August 5, 2016, the Company through a wholly owned subsidiary, acquired all of the membership interests in BioD, LLC (“BioD”) pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”) dated July 27, 2016. Initial consideration of $ 23,094,987 13,897,112 1,751,183 9,197,875 56,761,691 3,107,535 BioD is a vertically integrated company engaged in the development and commercialization of products derived from human placental tissues sold to surgeons, facilities and distributors serving the surgical, spine, orthopaedic, ocular and urological sectors of the healthcare marketplace. The Company has distributed certain of BioD’s products for dermal application in North America since January 2014 under a license, market development and commercialization agreement. This acquisition complemented the Company’s growth strategy aimed at expanding its portfolio of advanced wound care solutions and tissue regenerative technologies and enables the Company to sell directly into additional sectors of the healthcare marketplace. Assets acquired Accounts receivable $ 4,266,588 Inventory 979,713 Notes receivable 597,334 Prepaid expenses and other assets 158,198 Equipment and improvements 932,940 Acquired identifiable intangible assets 19,000,000 Goodwill 55,812,447 Total assets acquired 81,747,220 Current liabilities assumed Line of credit 1,420,254 Accounts payable 702,887 Accrued liabilities 1,917,525 Total liabilities assumed 4,040,666 Net assets acquired $ 77,706,554 Detail of total consideration Initial cash consideration (1) $ 13,897,112 Initial common stock consideration (1) 9,197,875 Settlement of pre-existing relationship (2) 903,408 Less BioD cash acquired (373,374) Net initial consideration 23,625,021 Contingent consideration (3) 54,081,533 Total consideration $ 77,706,554 (1) Initial consideration includes $ 2,000,000 1,178,846 440,054 (2) Reflects settlement of pre-existing relationship between the Company and BioD. (3) Includes the estimated fair value of potential product regulatory milestone payments in the aggregate estimated amount of up to $ 29,699,691 26,500,000 2,863,948 562,000 The following represents preliminary details of the fair value of acquired identifiable intangible assets purchased as part of the acquisition: Description Estimated Customer relationships 5 $ 10,000,000 Developed technology 10 6,000,000 Trade names 10 2,000,000 Non-compete agreements 3 1,000,000 Total acquired identifiable intangible assets $ 19,000,000 Determination of this preliminary allocation of the purchase price required management of the Company to make estimates and assumptions. The Company has engaged an independent valuation specialist to conduct an analysis to assist management in determining the estimated fair value of the acquired tangible and intangible assets, liabilities assumed, pre-existing relationships and contingent consideration. The work performed by the independent valuation specialist, while not complete, has been considered in management’s estimate of the fair values reflected above. The final purchase price allocation to reflect the fair values of the assets acquired and liabilities assumed will be based on completion of the Company’s valuation study, which is expected to be completed in the fourth quarter 2016. Finalization of the valuation analysis may result in fair values that differ materially from the preliminary estimates. The excess of the purchase price over the identifiable intangible and net tangible assets was allocated to goodwill. Goodwill recognized was primarily attributable to assets that do not qualify for separate recognition. The purchase price allocation is preliminary, pending the final determination of the fair value of certain assumed assets and liabilities, pre-existing relationships and contingent consideration. As these issues are identified, modified or resolved, resulting increases or decreases to the preliminary values are offset by a change to goodwill. Adjustments to these estimates will be included in the final allocation of the purchase price. All of the assets acquired, including goodwill, and liabilities assumed are included in the Advanced Wound Care Segment. Goodwill and identifiable intangible assets resulting from the acquisition are deductible for income tax purposes. Three months ended September 30, Nine months ended September 30, 2016 2015 2016 2015 (Unaudited) (Unaudited) Net sales $ 23,776,960 $ 22,131,402 $ 69,048,342 $ 63,074,631 Net loss from continuing operations $ (1,982,531) $ (4,653,899) $ (2,507,632) $ (17,044,443) Net loss from continuing operations per common share: basic and diluted $ (0.07) $ (0.17) $ (0.09) $ (0.63) Weighted average number of shares: basic and diluted 27,826,807 27,327,813 27,554,311 27,228,578 The nine months ended September 30, 2016 supplemental pro forma earnings were adjusted to exclude $ 2,892,713 1,866,667 2,400,000 1,751,183 229,919 The Company recorded net sales of $ 3,985,643 3,641,513 2,892,713 370,000 Untitled Letter On June 22, 2015, the U.S. Food and Drug Administration (“FDA”) issued an Untitled Letter alleging that BioD’s morselized amniotic membrane based products do not meet the criteria for regulation as human cellular tissue-based products (“HCT/Ps”) solely under Section 361 of the Public Health Service Act and that, as a result, BioD would need a biologics license to lawfully market those morselized products. Since the issuance of the Untitled Letter, BioD and more recently the Company have been in discussions with the FDA to communicate their disagreement with the FDA’s assertion that certain products are more than minimally manipulated. To date, the FDA has not changed its position that certain of the BioD acquired products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market these products but has also submitted a Request for Designation to determine if one of the morselized products should be regulated as a medical device or a biologic through the Biologics License Application (“BLA”) process. The Company also intends to pursue a BLA for another of the morselized products. On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The FDA held a public hearing on September 12 and 13, 2016 to obtain input on the Homologous Use draft guidance and the Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. If the FDA does allow the Company to continue to market its morselized products without a 510(k) clearance or biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions on marketing, such as labeling restrictions and compliance with cGMP. Compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a morselized product without a 510(k) clearance or biologics license even prior to finalization of the draft guidance documents, and could even require the Company to recall its morselized products. Net sales of the Company’s morselized products for the nine months ended September 30, 2016 and 2015 were approximately 13 12 In accordance with the Merger Agreement, BioD’s former members are entitled to receive additional consideration payable in cash and Company common stock of up to 35 29,699,691 i) specific FDA enforcement action is not received by the Company by May 5, 2017; or ii) specific FDA enforcement action is received by the Company prior to May 5, 2017 which does not require the Company to remove the morselized products from the market within 270 days of receipt of the FDA enforcement action; or iii) the Company is allowed to continue to market the morselized products while it fulfills FDA imposed requirements which were received prior to May 5, 2017 in lieu of the FDA exercising its enforcement discretion. In January 2014, the Company entered into a license, market development and commercialization agreement with BioD which granted to the Company an exclusive, perpetual, royalty-bearing license to use and sell BioD’s human placental based products for dermal applications. Royalties were payable to BioD under the agreement based upon a low double digit percentage of net sales. During 2016 the Company incurred royalties of $ 211,429 199,395

Restructuring and Other Charges

Restructuring and Other Charges	9 Months Ended
	Sep. 30, 2016
Restructuring Charges [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	4. Restructuring and Other Charges During the fourth quarter of 2015, the Company implemented a plan to reduce its cost structure in consideration of prospective market expectations for the business, coupled with the decision to move the business towards positive cash flow and profitability as soon as feasibly possible. The restructuring plan included the elimination of 39 Effective December 21, 2015, the Company’s Chairman of the Board, President and Chief Executive Officer (“CEO”) departed from the Company. On February 26, 2016, the former CEO resigned from the Company’s Board of Directors. While a national recruiting search for a permanent CEO is in process, the former lead director of the Company has assumed the role of Executive Chairman and Interim CEO. CEO Other Employees Total Balance, January 1, 2016 $ 1,252,105 $ 826,932 $ 2,079,037 Charges during period - - - Payments during period (506,366) (816,544) (1,322,910) Balance, September 30, 2016 $ 745,739 $ 10,388 $ 756,127 Less current portion (599,008) (10,388) (609,396) Long term portion $ 146,731 $ - $ 146,731

Cash and Cash Equivalents and I

Cash and Cash Equivalents and Investments	9 Months Ended
	Sep. 30, 2016
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Cash, Cash Equivalents, and Short-term Investments [Text Block]	5. Cash and Cash Equivalents and Investments Cash and Cash Equivalents The Company considers cash and cash equivalents as amounts on hand, on deposit in financial institutions and highly liquid investments purchased with an original maturity of three months or less. The Company maintains cash and cash equivalents and money market mutual funds with various domestic and foreign financial institutions within the ordinary course of business, which at times may exceed jurisdictional insurance limits. Money market mutual funds consist of funds deposited into mutual funds investing in U.S. government and non-government obligations. Investments in Debt Securities Investments in debt securities include certificates of deposit purchased with an original maturity greater than three months which are deposited in various U.S. financial institutions and are fully insured by the Federal Deposit Insurance Corporation. The Company intends to hold the certificates of deposit to maturity and accordingly these investments are carried at amortized cost. Investments in debt securities with maturities greater than one year from the balance sheet date are classified as a long-term asset. Investment in Equity Securities In 2013 and 2014, the Company purchased an aggregate 2,802,277 8,483,693 7,594,158 925,000 4,740,136 1,877,277 5.0 The investment in Comvita common stock is classified as an available-for-sale investment carried at fair value, with any unrealized gains and losses associated with the investment included in accumulated other comprehensive income (loss) and any dividends received recorded in other income, net in the Consolidated Statements of Operations. The investment is classified as a long term asset. As of September 30, 2016, the fair value of the Comvita common stock was $ 15,426,148 9,796,477 September 30, 2016 December 31, 2015 Cash $ 20,974,166 $ 10,784,522 Cash equivalents 5,000,000 5,029,683 Cash and cash equivalents 25,974,166 15,814,205 Investments in debt securities 15,000,000 25,003,990 Investment in equity securities 15,426,148 16,110,178 Total investments 30,426,148 41,114,168 Total cash and cash equivalents and investments $ 56,400,314 $ 56,928,373 Fair Value Measurements, Using Total carrying Quoted prices Significant other Significant Cash and cash equivalents $ 25,974,166 $ 25,974,166 $ - $ - Investments in debt securities 15,000,000 15,000,000 - - Investment in equity securities 15,426,148 15,426,148 - - Total investments 30,426,148 30,426,148 - - Total $ 56,400,314 $ 56,400,314 $ - $ - The following table provides fair value information as of December 31, 2015: Fair Value Measurements, Using Total carrying Quoted prices Significant other Significant Cash and cash equivalents $ 15,814,205 $ 15,814,205 $ - $ - Investments in debt securities 25,003,990 25,003,990 - - Investment in equity securities 16,110,178 16,110,178 - - Total investments 41,114,168 41,114,168 - - Total $ 56,928,373 $ 56,928,373 $ - $ - Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets. Level 2 inputs are quoted prices for similar assets in active markets or inputs that are observable for the asset, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management’s own assumptions used to measure assets at fair value. A financial asset’s classification is determined based on the lowest level input that is significant to the fair value measurement.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	6. Inventories Inventories include the following: September 30, December 31, Finished goods and available tissue for distribution $ 8,302,804 $ 11,039,877 Goods and tissue in process 974,061 346,233 Packaging materials 1,489,483 1,152,993 Raw materials 3,626,825 3,811,910 Total inventories $ 14,393,173 $ 16,351,013

Notes Receivable

Notes Receivable	9 Months Ended
	Sep. 30, 2016
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	7. Notes Receivable September 30, December 31, 10% interest bearing note receivable in monthly installments of $87,121 through September 2019 received in connection with FAD divestiture $ 2,700,000 $ - Non-interest bearing notes receivable in monthly installments of $10,556 through June 2019 assumed in connection with the BioD acquisition 325,556 - $ 3,025,556 - Less current portion (938,677) - $ 2,086,879 $ -

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	9 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	8. Accrued Expenses and Other Liabilities September 30, December 31, Accrued compensation and related taxes $ 3,964,908 $ 2,298,080 Liabilities related to restructuring (Note 4) 756,127 2,079,037 Accrued sales incentives and other fees 574,620 385,573 Accrued royalties 482,025 510,901 Other 2,914,373 2,038,478 Total accrued expenses and other liabilities $ 8,692,053 $ 7,312,069 Less current portion (8,193,998) (6,297,691) Long term liabilities $ 498,055 $ 1,014,378

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9. Stockholders’ Equity Preferred Stock Subsequent to the issuances of its preferred stock, the Company has undertaken a number of common stock offerings that impact the preferred stock conversion ratios. As of September 30, 2016, current Series A and B preferred stockholders holding 73,332 123,114 49,782 Upon conversion, the 49,782 incremental shares associated with the conversion ratio adjustments will be recorded to common stock at par with the offset to additional paid in capital as all of the convertible preferred stock was issued prior to the November 16, 2000 effective date of certain provisions of Accounting Standards Codification 470 (formerly Emerging Issues Task Force Issue No. 00-27 Application of Issue No. 98-5 to Certain Convertible Instruments) Common Stock During the nine months ended September 30, 2016, the Company issued 2,392,355 1,751,183 551,665 84,874 90,450 4,633 12,300 On August 5, 2016, the Company received net cash proceeds of $ 2,233,567 66,433 551,665 Stock Purchase Warrants At September 30, 2016, there were no warrants outstanding. During the nine months ended September 30, 2016 no warrants were exercised, 1,705,330 50,000 Equity Based Compensation Under the Derma Sciences, Inc. 2012 Equity Incentive Plan (the “EIP Plan”) the Company is authorized to issue 6,000,000 2,708,002 343,050 1,725,781 Stock Options The EIP Plan permits the granting of both incentive and nonqualified stock options to employees and nonqualified stock options to non-employee directors and consultants of the Company. The option exercise price may not be less than the fair market value of the stock on the date of the grant of the option. The duration of each option may not exceed 10 Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Risk-free interest rate 1.34 % 1.85 % 1.41 % 1.61 % Volatility factor 43.8 % 45.4 % 43.9 % 45.7 % Dividend yield 0 % 0 % 0 % 0 % Expected option life (years) 3.69 6.25 5.10 5.70 The risk-free rate utilized represents the U.S. treasury yield curve rate for the expected option life at the time of grant. The volatility factor was calculated based on the Company’s historical stock price volatility equal to the expected life of the option at the grant date. The dividend yield is 0 Based on the Company’s historical experience of options that were forfeited before becoming fully vested, the Company has assumed an annualized forfeiture rate of 1.0 Options Weighted Average Outstanding – January 1, 2016 2,301,760 $ 9.04 Granted 813,660 $ 3.86 Forfeited (130,862) $ 5.87 Exercised (7,475) $ 3.23 Expired (269,081) $ 9.26 Outstanding – September 30, 2016 2,708,002 $ 7.63 Expected to vest – September 30, 2016 2,680,922 $ 7.63 Exercisable at September 30, 2016 1,967,556 $ 8.42 During the nine months ended September 30, 2016, the Company granted 611,260 202,400 1.60 During the nine months ended September 30, 2016, 7,475 stock options were exercised on a for-cash and cashless basis. A total of 4,633 shares of common stock were issued in connection with the stock option exercises. The intrinsic value of options exercised in 2016 was $ 5,755 Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Cost of sales $ 26,406 $ 23,740 $ 87,170 $ 109,047 Selling, general and administrative expenses 117,094 518,336 810,831 1,828,480 Discontinued operations (28,333) 23,258 (7,940) 106,238 Total stock option compensation expense $ 115,167 $ 565,334 $ 890,061 $ 2,043,765 As of September 30, 2016, there was $ 1,034,531 158,868 2.0 1.6 Restricted Share Units The Company has issued service, performance and market-based restricted share units to employees, consultants and directors of the Company. Expense for restricted share awards is amortized on a straight-line basis over the awards’ vesting period. The fair value of service and performance awards are determined using the quoted market price of the Company’s common stock on the date of grant, while market based performance awards are valued using a binomial/lattice pricing mode. Number of Weighted Average Fair Value Unvested – January 1, 2016 152,750 $ 8.59 Granted 301,800 $ 4.63 Vested (90,450) $ 7.50 Cancelled (21,050) $ 7.00 Unvested – September 30, 2016 343,050 $ 5.49 In connection with the vesting of restricted share unit awards during the nine months ended September 30, 2016, 5,576 18,010 During the three months ended September 30, 2016 and 2015, restricted share unit compensation expense was $ 257,833 652,286 807,589 1,971,993 As of September 30, 2016, the intrinsic value of the non-vested awards was $ 1,602,044 1,213,469 1.7 In July of 2016, in consideration of prior service to the Company, the Company accelerated the vesting of all unvested stock options of a departing executive. An additional $ 49,035 In May of 2016, in consideration of prior service to the Company, the Company granted two retiring directors 30,000 48,733 In May of 2015, in consideration of prior service to the Company, the Company granted a retiring director 15,000 70,670 Shares Reserved for Future Issuance Convertible preferred stock (series A – B) 73,332 Additional stock issuable related to conversion of preferred stock (series A – B) 49,782 Common stock options outstanding 2,708,002 Restricted share units outstanding 343,050 Common stock equivalents available for grant 1,725,781 Total common stock shares reserved 4,899,947

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Comprehensive Income (Loss) Note [Text Block]	10. Accumulated Other Comprehensive Income The Company’s accumulated other comprehensive income as of September 30, 2016 was as follows: Foreign Currency Translation Unrealized Gain on Equity Securities, Total Balance at January 1, 2016 $ 555,938 $ 4,716,970 $ 5,272,908 Other comprehensive income before reclassification 575,471 4,332,818 4,908,289 Amounts reclassified from accumulated other comprehensive income - (2,975,813) (2,975,813) Balance at September 30, 2016 $ 1,131,409 $ 6,073,975 $ 7,205,384 Amount reclassified from accumulated other Affected line item in the consolidated statements Unrealized gain on equity securities, net of taxes Realized gain on equity securities $ (4,758,636) Other income, net Income tax provision 1,782,823 Income tax provision Total reclassification $ (2,975,813)

Operating Segments

Operating Segments	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	11. Operating Segments The Company operates in two segments: advanced wound care and traditional wound care. They are managed separately as each segment requires different technology, marketing and sales strategies. Advanced wound care products principally consist of both novel and otherwise differentiated human placental based products, dressings, and other medical devices designed to promote wound healing and/or prevent infection. Traditional wound care products principally consist of commodity dressings, ointments, gauze bandages, adhesive bandages, wound closure strips and catheter fasteners. Advanced and traditional wound care products are marketed globally to acute care, extended care, home health care, wound and burn care clinics and physician offices. The Company utilizes a broad network of well-established distributors to deploy the majority of its products to end users. A smaller portion of the Company’s products are sold directly to care providers and through retail. The advanced and traditional wound care products are either manufactured internally or sourced from third party suppliers. The majority of marketing expenses are deployed in support of advanced wound care products with traditional wound care products requiring more limited support. The Company utilizes direct and independent sales representatives, distributor relationships and contractual relationships with buying groups and wound care service providers to sell its products. The Company uses direct sales representatives for medical device sales, and independent sales representatives for sales of placental tissue products in the U.S. In Canada and the U.K., the Company relies on direct sales representatives for both advanced and traditional wound care products. Each operating segment is managed at the segment contribution level consisting of gross profit minus direct expense consisting of distribution, marketing, sales, research and development, intangible amortization expenses, change in fair value of contingent consideration, and acquisition related expenses. The advanced wound care segment consists of two reporting units, while the traditional wound care segment consists of one reporting unit. Expenses are allocated directly by reporting unit to the extent possible. Expenses common to operating segments/reporting units are allocated consistently using activity based assumptions. The aggregation or allocation of indirect expenses by segment/reporting unit is not practical. Three Months Ended September 30, 2016 Advanced Traditional Other Total Net sales $ 15,789,683 $ 6,019,843 $ - $ 21,809,526 Gross profit 9,419,831 1,286,631 - 10,706,462 Direct expense (1) (12,744,522) (425,253) - (13,169,775) Segment contribution $ (3,324,691) $ 861,378 - (2,463,313) Indirect expenses, net $ (2,109,986) (2,109,986) Net loss from continuing operations $ (4,573,299) Three Months Ended September 30, 2015 Net sales $ 11,348,591 $ 6,438,936 $ - $ 17,787,527 Gross profit 5,496,935 1,798,660 - 7,295,595 Direct expense (7,957,641) (766,150) - (8,723,791) Segment contribution $ (2,460,706) $ 1,032,510 - (1,428,196) Indirect expenses, net $ (3,245,845) (3,245,845) Net loss from continuing operations $ (4,674,041) Nine Months Ended September 30, 2016 Advanced Traditional Other Total Net sales $ 37,364,124 $ 18,161,608 $ - $ 55,525,732 Gross profit 20,655,523 4,115,980 - 24,771,503 Direct expense (1) (24,987,258) (1,483,895) - (26,471,153) Segment contribution $ (4,331,735) $ 2,632,085 - (1,699,650) Indirect expenses, net $ (3,257,218) (3,257,218) Net loss from continuing operations $ (4,956,868) Nine Months Ended September 30, 2015 Net sales $ 31,411,631 $ 19,960,008 $ - $ 51,371,639 Gross profit 15,260,095 5,801,081 - 21,061,176 Direct expense (25,173,533) (2,290,675) - (27,464,208) Segment contribution $ (9,913,438) $ 3,510,406 - (6,403,032) Indirect expenses, net $ (10,697,366) (10,697,366) Net loss from continuing operations $ (17,100,398) The advanced wound care segment includes acquisition related costs of $ 2,734,653 2,892,713 370,000 370,000 Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 United States 83 % 84 % United States 80 % 84 % Canada 11 % 11 % Canada 13 % 11 % Rest of World 6 % 5 % Rest of World 7 % 5 % For the three months ended September 30, 2016 and 2015, the Company had a major Canadian customer comprising 11 11 13 11

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	12. Income Taxes Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Current tax expense $ (31,315) $ (170,082) $ (260,190) $ (252,735) Deferred tax benefit 1,487,592 1,221,974 1,654,310 1,007,843 Income tax benefit (expense) $ 1,456,277 $ 1,051,892 $ 1,394,120 $ 755,108 Effective tax rate (24.2) % (18.4) % (22.0) % (4.2) % For the three months ended September 30, 2016, the Company recognized an income tax benefit consisting of a U.S. and foreign income tax benefit. For the nine months ended September 30, 2016, the Company recognized income tax expense consisting of a U.S. tax benefit and foreign income tax expense. The U.S. income tax benefit relates to the tax impact of the loss generated from continuing operations and the unrealized gain on equity securities from accumulated other comprehensive income partially offset by the tax treatment of goodwill net of amortization for financial reporting but not tax purposes of acquired identified intangible assets. The foreign income tax expense relates to income taxes recognized as a result of income recognized by the Canadian operations and taxes paid on a dividend from the Comvita investment. For the three and nine months ended September 30, 2015, the Company recognized an income tax benefit consisting of a U.S. income tax benefit and a foreign income tax expense. The U.S. income tax benefit relates to a reduction in the Company’s U.S. valuation allowance due to the tax impact of the unrealized gain on equity securities included in accumulated other comprehensive income. The foreign income tax expense relates to income taxes recognized as a result of income recognized by the Canadian operations and taxes paid on a dividend from the Comvita investment.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	13. Commitments and Contingencies Comvita Licensing Agreement In February 2010, the Company entered into a new agreement with Comvita (the “Comvita Agreement”) under which the Company received perpetual and exclusive worldwide licensing rights for Manuka Honey based MEDIHONEY wound and skin care products for all markets outside of the consumer market. The Comvita Agreement also provides that Comvita will serve as the Company’s supplier for Manuka Honey and will not provide Manuka Honey to any other entities for use in the professional medical-surgical marketplace. The Comvita Agreement calls for graduated royalty payments based on sales and milestone payments. The license rights may be terminated or rendered non-exclusive by Comvita if the Company fails to meet certain minimum royalty requirements. Comvita is a stockholder of the Company. The Company purchased $ 1,879,332 2,626,705 1,136,498 1,086,392 973,156 506,795 Canadian Distribution Agreement In May 2005, the Company entered into a distribution agreement with a Canadian company to serve as the exclusive distributor of its products in Canada. The agreement also appoints the distributor as the Company’s Canadian servicing agent to fulfill supply contracts held directly by the Company. The agreement was amended to extend the term from September 1, 2016 through August 31, 2019. As part of the amendment, the Canadian company became a non-exclusive distributor of the Company’s products. The Company recognizes revenue under the agreement when title and risk of loss pass to the distributor and collectability is reasonably assured, which is at the time product is shipped to the distributor. Payment terms from the distributor are 0.9% 30 days, net 45 days. Either party has the right to terminate the agreement when an event of default (as defined) has occurred with respect to the other party. The distributor is entitled to continue to sell or otherwise dispose of all inventory owned by it from and after the date of contract expiration or termination. If termination of the agreement is not occasioned by breach by the distributor, the distributor will be entitled on notice to the Company to return saleable inventory (as defined) to the Company. At September 30, 2016, the distributor’s inventory of Company products was approximately $ 2,050,000 Employment Agreement In July 2016 the Company recognized compensation expense included in selling, general and administrative expenses of $ 483,669 434,634 49,035 Contingencies On occasion, the Company is involved in claims and other legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations, or liquidity.

Organization and Summary of S21

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting, Policy [Policy Text Block]	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. Information included in the consolidated balance sheet as of December 31, 2015 has been derived from the consolidated financial statements and footnotes thereto for the year ended December 31, 2015, included in the Annual Report on Form 10-K previously filed with the Securities and Exchange Commission. For further information refer to the Annual Report on Form 10-K for the year ended December 31, 2015.
Principles of Consolidation, Policy [Policy Text Block]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
Business Combinations Policy [Policy Text Block]	Acquisitions Contingent consideration is recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent payments are recognized in earnings. Contingent payments related to acquisitions consist of regulatory milestones and an earnout based on sales.
Net Loss Per Share, Policy [Policy Text Block]	Net Income (Loss) per Share Three and Nine Months Ended September 30, 2016 2015 Excluded dilutive shares: Convertible preferred stock 73,332 73,332 Additional stock issuable related to conversion of preferred stock 49,782 49,782 Restricted share units 343,050 674,500 Warrants - 1,755,330 Stock options 2,708,002 2,472,491 Common stock held in escrow 229,919 - Total dilutive shares 3,404,085 5,025,435
Recently Issued Accounting Pronouncements, Policy [Policy Text Block]	Revenue from Contracts with Customers In January 2016, the FASB issued ASU No. 2016-01, Accounting for Equity Investments and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. There are no other recently issued accounting pronouncements that are expected to have a material effect on the Company's financial position, results of operations or cash flows.

Organization and Summary of S22

Organization and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Potentially Dilutive Shares Excluded as Result of Effects Being Anti-dilutive [Table Text Block]	Three and Nine Months Ended September 30, 2016 2015 Excluded dilutive shares: Convertible preferred stock 73,332 73,332 Additional stock issuable related to conversion of preferred stock 49,782 49,782 Restricted share units 343,050 674,500 Warrants - 1,755,330 Stock options 2,708,002 2,472,491 Common stock held in escrow 229,919 - Total dilutive shares 3,404,085 5,025,435

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations Relating to Gain on Sale Of Assets [Table Text Block]	3,755,205 Consideration Cash $ 9,670,995 Note receivable 2,700,000 Total consideration received 12,370,995 Less: Inventory 3,370,995 Fixed assets 90,309 Goodwill 4,679,684 Amortizable intangible assets 340,057 Deferred rent (14,835) Transaction costs 149,580 Net gain on sale before taxes $ 3,755,205
Disposal Groups, Including Discontinued Operations [Table Text Block]	Summarized operating results of FAD discontinued operations are presented in the following table: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Net sales $ 2,966,753 $ 4,381,140 $ 11,701,166 $ 12,852,036 Cost of sales 2,265,229 3,240,485 9,097,311 9,570,595 Gross profit 701,524 1,140,655 2,603,855 3,281,441 Selling, general and administrative 439,866 549,453 1,488,272 1,723,061 Income from discontinued operations before income taxes 261,658 591,202 1,115,583 1,558,380 Summarized assets and liabilities of FAD discontinued operations are presented in the following table: September 30, 2016 December 31, 2015 Accounts receivable, net $ 556,614 $ 1,838,441 Inventory, net - 4,339,692 Prepaid expenses 21,148 993,962 Total current assets 577,762 7,172,095 Equipment and improvements, net - 103,396 Identifiable intangible assets, net - 390,057 Goodwill - 4,679,684 Other assets - 48,552 Total non-current assets - 5,221,689 Accounts payable 1,528 140,831 Accrued expenses 53,538 393,648 Total current liabilities 55,066 534,479 Deferred tax liability - 883,637 Total long-term liabilities $ - $ 883,637

Acquisition of BioD, LLC (Table

Acquisition of BioD, LLC (Tables)	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The transaction was accounted for as a purchase of the net assets of BioD. Accordingly, the results of operations of BioD have been included in the consolidated financial statements commencing August 5, 2016. A preliminary allocation of the purchase price to the estimated fair values of the assets acquired and the liabilities assumed is outlined below: Assets acquired Accounts receivable $ 4,266,588 Inventory 979,713 Notes receivable 597,334 Prepaid expenses and other assets 158,198 Equipment and improvements 932,940 Acquired identifiable intangible assets 19,000,000 Goodwill 55,812,447 Total assets acquired 81,747,220 Current liabilities assumed Line of credit 1,420,254 Accounts payable 702,887 Accrued liabilities 1,917,525 Total liabilities assumed 4,040,666 Net assets acquired $ 77,706,554 Detail of total consideration Initial cash consideration (1) $ 13,897,112 Initial common stock consideration (1) 9,197,875 Settlement of pre-existing relationship (2) 903,408 Less BioD cash acquired (373,374) Net initial consideration 23,625,021 Contingent consideration (3) 54,081,533 Total consideration $ 77,706,554 (1) Initial consideration includes $ 2,000,000 1,178,846 440,054 (2) Reflects settlement of pre-existing relationship between the Company and BioD. (3) Includes the estimated fair value of potential product regulatory milestone payments in the aggregate estimated amount of up to $ 29,699,691 26,500,000 2,863,948 562,000
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The following represents preliminary details of the fair value of acquired identifiable intangible assets purchased as part of the acquisition: Description Estimated Customer relationships 5 $ 10,000,000 Developed technology 10 6,000,000 Trade names 10 2,000,000 Non-compete agreements 3 1,000,000 Total acquired identifiable intangible assets $ 19,000,000
Business Acquisition, Pro Forma Information [Table Text Block]	The unaudited pro forma information below presents combined results of operations as if the acquisition had occurred at the beginning of the periods presented instead of August 5, 2016. The pro forma information is based on historical results adjusted for the effect of acquisition accounting and is not necessarily indicative of the results of operations of the combined entity had the acquisition occurred at the beginning of the periods presented, nor is it necessarily indicative of future results. Three months ended September 30, Nine months ended September 30, 2016 2015 2016 2015 (Unaudited) (Unaudited) Net sales $ 23,776,960 $ 22,131,402 $ 69,048,342 $ 63,074,631 Net loss from continuing operations $ (1,982,531) $ (4,653,899) $ (2,507,632) $ (17,044,443) Net loss from continuing operations per common share: basic and diluted $ (0.07) $ (0.17) $ (0.09) $ (0.63) Weighted average number of shares: basic and diluted 27,826,807 27,327,813 27,554,311 27,228,578

Restructuring and Other Charg25

Restructuring and Other Charges (Tables)	9 Months Ended
	Sep. 30, 2016
Restructuring Charges [Abstract]
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	CEO Other Employees Total Balance, January 1, 2016 $ 1,252,105 $ 826,932 $ 2,079,037 Charges during period - - - Payments during period (506,366) (816,544) (1,322,910) Balance, September 30, 2016 $ 745,739 $ 10,388 $ 756,127 Less current portion (599,008) (10,388) (609,396) Long term portion $ 146,731 $ - $ 146,731

Cash and Cash Equivalents and26

Cash and Cash Equivalents and Investments (Tables)	9 Months Ended
	Sep. 30, 2016
Cash, Cash Equivalents, and Short-term Investments [Abstract]
Schedule Of Cash And Cash Equivalents And Investments [Table Text Block]	Cash and cash equivalents and investments at September 30, 2016 and December 31, 2015 consisted of the following: September 30, 2016 December 31, 2015 Cash $ 20,974,166 $ 10,784,522 Cash equivalents 5,000,000 5,029,683 Cash and cash equivalents 25,974,166 15,814,205 Investments in debt securities 15,000,000 25,003,990 Investment in equity securities 15,426,148 16,110,178 Total investments 30,426,148 41,114,168 Total cash and cash equivalents and investments $ 56,400,314 $ 56,928,373
Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]	The following table provides fair value information as of September 30, 2016: Fair Value Measurements, Using Total carrying Quoted prices Significant other Significant Cash and cash equivalents $ 25,974,166 $ 25,974,166 $ - $ - Investments in debt securities 15,000,000 15,000,000 - - Investment in equity securities 15,426,148 15,426,148 - - Total investments 30,426,148 30,426,148 - - Total $ 56,400,314 $ 56,400,314 $ - $ - The following table provides fair value information as of December 31, 2015: Fair Value Measurements, Using Total carrying Quoted prices Significant other Significant Cash and cash equivalents $ 15,814,205 $ 15,814,205 $ - $ - Investments in debt securities 25,003,990 25,003,990 - - Investment in equity securities 16,110,178 16,110,178 - - Total investments 41,114,168 41,114,168 - - Total $ 56,928,373 $ 56,928,373 $ - $ -

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories include the following: September 30, December 31, Finished goods and available tissue for distribution $ 8,302,804 $ 11,039,877 Goods and tissue in process 974,061 346,233 Packaging materials 1,489,483 1,152,993 Raw materials 3,626,825 3,811,910 Total inventories $ 14,393,173 $ 16,351,013

Notes Receivable (Tables)

Notes Receivable (Tables)	9 Months Ended
	Sep. 30, 2016
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	Notes receivable include the following: September 30, December 31, 10% interest bearing note receivable in monthly installments of $87,121 through September 2019 received in connection with FAD divestiture $ 2,700,000 $ - Non-interest bearing notes receivable in monthly installments of $10,556 through June 2019 assumed in connection with the BioD acquisition 325,556 - $ 3,025,556 - Less current portion (938,677) - $ 2,086,879 $ -

Accrued Expenses and Other Li29

Accrued Expenses and Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Current Liabilities [Table Text Block]	Accrued expenses and other liabilities include the following: September 30, December 31, Accrued compensation and related taxes $ 3,964,908 $ 2,298,080 Liabilities related to restructuring (Note 4) 756,127 2,079,037 Accrued sales incentives and other fees 574,620 385,573 Accrued royalties 482,025 510,901 Other 2,914,373 2,038,478 Total accrued expenses and other liabilities $ 8,692,053 $ 7,312,069 Less current portion (8,193,998) (6,297,691) Long term liabilities $ 498,055 $ 1,014,378

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Risk-free interest rate 1.34 % 1.85 % 1.41 % 1.61 % Volatility factor 43.8 % 45.4 % 43.9 % 45.7 % Dividend yield 0 % 0 % 0 % 0 % Expected option life (years) 3.69 6.25 5.10 5.70
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Weighted Average Outstanding – January 1, 2016 2,301,760 $ 9.04 Granted 813,660 $ 3.86 Forfeited (130,862) $ 5.87 Exercised (7,475) $ 3.23 Expired (269,081) $ 9.26 Outstanding – September 30, 2016 2,708,002 $ 7.63 Expected to vest – September 30, 2016 2,680,922 $ 7.63 Exercisable at September 30, 2016 1,967,556 $ 8.42
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	During the three and nine months ended September 30, 2016 and 2015, stock option compensation expense was recorded as follows: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Cost of sales $ 26,406 $ 23,740 $ 87,170 $ 109,047 Selling, general and administrative expenses 117,094 518,336 810,831 1,828,480 Discontinued operations (28,333) 23,258 (7,940) 106,238 Total stock option compensation expense $ 115,167 $ 565,334 $ 890,061 $ 2,043,765
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	The following table summarizes the restricted share unit activity for the period: Number of Weighted Average Fair Value Unvested – January 1, 2016 152,750 $ 8.59 Granted 301,800 $ 4.63 Vested (90,450) $ 7.50 Cancelled (21,050) $ 7.00 Unvested – September 30, 2016 343,050 $ 5.49
Schedule Of Common Stock Shares Reserved For Issuance And Shares Available For Grant [Table Text Block]	Convertible preferred stock (series A – B) 73,332 Additional stock issuable related to conversion of preferred stock (series A – B) 49,782 Common stock options outstanding 2,708,002 Restricted share units outstanding 343,050 Common stock equivalents available for grant 1,725,781 Total common stock shares reserved 4,899,947

Accumulated Other Comprehensi31

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The Company’s accumulated other comprehensive income as of September 30, 2016 was as follows: Foreign Currency Translation Unrealized Gain on Equity Securities, Total Balance at January 1, 2016 $ 555,938 $ 4,716,970 $ 5,272,908 Other comprehensive income before reclassification 575,471 4,332,818 4,908,289 Amounts reclassified from accumulated other comprehensive income - (2,975,813) (2,975,813) Balance at September 30, 2016 $ 1,131,409 $ 6,073,975 $ 7,205,384
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	Amount reclassified from accumulated other Affected line item in the consolidated statements Unrealized gain on equity securities, net of taxes Realized gain on equity securities $ (4,758,636) Other income, net Income tax provision 1,782,823 Income tax provision Total reclassification $ (2,975,813)

Operating Segments (Tables)

Operating Segments (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Three Months Ended September 30, 2016 Advanced Traditional Other Total Net sales $ 15,789,683 $ 6,019,843 $ - $ 21,809,526 Gross profit 9,419,831 1,286,631 - 10,706,462 Direct expense (1) (12,744,522) (425,253) - (13,169,775) Segment contribution $ (3,324,691) $ 861,378 - (2,463,313) Indirect expenses, net $ (2,109,986) (2,109,986) Net loss from continuing operations $ (4,573,299) Three Months Ended September 30, 2015 Net sales $ 11,348,591 $ 6,438,936 $ - $ 17,787,527 Gross profit 5,496,935 1,798,660 - 7,295,595 Direct expense (7,957,641) (766,150) - (8,723,791) Segment contribution $ (2,460,706) $ 1,032,510 - (1,428,196) Indirect expenses, net $ (3,245,845) (3,245,845) Net loss from continuing operations $ (4,674,041) Nine Months Ended September 30, 2016 Advanced Traditional Other Total Net sales $ 37,364,124 $ 18,161,608 $ - $ 55,525,732 Gross profit 20,655,523 4,115,980 - 24,771,503 Direct expense (1) (24,987,258) (1,483,895) - (26,471,153) Segment contribution $ (4,331,735) $ 2,632,085 - (1,699,650) Indirect expenses, net $ (3,257,218) (3,257,218) Net loss from continuing operations $ (4,956,868) Nine Months Ended September 30, 2015 Net sales $ 31,411,631 $ 19,960,008 $ - $ 51,371,639 Gross profit 15,260,095 5,801,081 - 21,061,176 Direct expense (25,173,533) (2,290,675) - (27,464,208) Segment contribution $ (9,913,438) $ 3,510,406 - (6,403,032) Indirect expenses, net $ (10,697,366) (10,697,366) Net loss from continuing operations $ (17,100,398) The advanced wound care segment includes acquisition related costs of $ 2,734,653 2,892,713 370,000 370,000
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 United States 83 % 84 % United States 80 % 84 % Canada 11 % 11 % Canada 13 % 11 % Rest of World 6 % 5 % Rest of World 7 % 5 %

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Tax Expense [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Current tax expense $ (31,315) $ (170,082) $ (260,190) $ (252,735) Deferred tax benefit 1,487,592 1,221,974 1,654,310 1,007,843 Income tax benefit (expense) $ 1,456,277 $ 1,051,892 $ 1,394,120 $ 755,108 Effective tax rate (24.2) % (18.4) % (22.0) % (4.2) %

Organization and Summary of S34

Organization and Summary of Significant Accounting Policies (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,404,085	5,025,435	3,404,085	5,025,435
Convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	73,332	73,332	73,332	73,332
Additional stock issuable related to conversion of preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	49,782	49,782	49,782	49,782
Restricted share units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	343,050	674,500	343,050	674,500
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	1,755,330	0	1,755,330
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,708,002	2,472,491	2,708,002	2,472,491
Common stock held in escrow [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	229,919	0	229,919	0

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	[1]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash	$ 9,521,415	$ 0
Inventory	14,393,173		$ 16,351,013
Fixed assets	4,474,165		4,025,811
Goodwill	64,590,456		$ 8,778,009
Amortizable intangible assets	(2,636,176)	$ (2,238,194)
First Aid Division [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash	9,670,995
Note receivable	2,700,000
Total consideration received	12,370,995
Inventory	3,370,995
Fixed assets	90,309
Goodwill	4,679,684
Amortizable intangible assets	340,057
Deferred rent	(14,835)
Transaction costs	149,580
Net gain on sale before taxes	$ 3,755,205
[1]	Reclassified for discontinued operations. See note 2.

Discontinued Operations (Deta36

Discontinued Operations (Details 1) - First Aid Division [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	$ 2,966,753	$ 4,381,140	$ 11,701,166	$ 12,852,036
Cost of sales	2,265,229	3,240,485	9,097,311	9,570,595
Gross profit	701,524	1,140,655	2,603,855	3,281,441
Selling, general and administrative	439,866	549,453	1,488,272	1,723,061
Income from discontinued operations before taxes	$ 261,658	$ 591,202	$ 1,115,583	$ 1,558,380

Discontinued Operations (Deta37

Discontinued Operations (Details 2) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net	$ 556,614	$ 1,838,441
Inventory, net	0	4,339,692
Prepaid expenses	21,148	993,962
Total current assets	577,762	7,172,095	[1]
Equipment and improvements, net	0	103,396
Identifiable intangible assets, net	0	390,057
Goodwill	0	4,679,684
Other assets	0	48,552
Total non-current assets	0	5,221,689	[1]
Accounts payable	1,528	140,831
Accrued expenses	53,538	393,648
Total current liabilities	120,192	4,905,489	[1]
Deferred tax liability	0	883,637
Total long-term liabilities	$ 0	$ 883,637	[1]
[1]	Reclassified for discontinued operations. See note 2.

Discontinued Operations (Deta38

Discontinued Operations (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Severance Costs	$ 65,126		$ 4,371,010
Amortization of Intangible Assets	2,636,176	$ 2,238,194
Proceeds from Divestiture of Businesses	9,521,415	0
Gain (Loss) on Disposition of Assets	3,755,205	0
First Aid Division [Member]
Amortization of Intangible Assets	(340,057)
Proceeds from Divestiture of Businesses	9,670,995
Divestiture of Business, Consideration Received Other Than Cash	2,700,000
Gain (Loss) on Disposition of Assets	3,755,205
Dukal Corporation [Member]
Other Receivables	25,000
Cost of Sales [Member]
Depreciation	17,780	22,255
Selling, General and Administrative Expenses [Member]
Amortization of Intangible Assets	$ 50,000	$ 56,250

Acquisition of BioD, LLC (Detai

Acquisition of BioD, LLC (Details) - USD ($)		Aug. 05, 2016		Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2015	[1]
Assets acquired
Goodwill				$ 64,590,456	$ 64,590,456	$ 64,590,456	$ 8,778,009
BioD,LLC [Member]
Assets acquired
Accounts receivable		$ 4,266,588
Inventory		979,713
Notes receivable		597,334
Prepaid expenses and other assets		158,198
Equipment and improvements		932,940
Acquired identifiable intangible assets		19,000,000		19,000,000	19,000,000	19,000,000
Goodwill		55,812,447
Total assets acquired		81,747,220
Current liabilities assumed
Line of credit		1,420,254
Accounts payable		702,887
Accrued liabilities		1,917,525
Total liabilities assumed		4,040,666
Net assets acquired		77,706,554		29,699,691
Initial cash consideration	[2]	13,897,112
Initial common stock consideration	[2]	9,197,875
Settlement of pre-existing relationship		903,408	[3]		$ 370,000	$ 370,000
Less BioD cash acquired		(373,374)
Net initial consideration		23,625,021
Contingent consideration	[4]	54,081,533
Total consideration		$ 77,706,554		$ 29,699,691
[1]	Reclassified for discontinued operations. See note 2.
[2]	Initial consideration includes $2,000,000 held in escrow to secure BioD payment obligations for working capital adjustments and any indemnification claims and $1,178,846 held in escrow pending the collection of two separate classes of accounts receivable. Amounts equal to the collected receivables through August 5, 2017 will be released to the sellers from the accounts receivable escrows with the remainder returned to the Company by September 4, 2017. In September 2016, the Company received $440,054 for working capital adjustments from these reserves.
[3]	Reflects settlement of pre-existing relationship between the Company and BioD.
[4]	Includes the estimated fair value of potential product regulatory milestone payments in the aggregate estimated amount of up to $29,699,691 and net sales growth earnouts for the trailing twelve months ending June 30, 2017 and 2018 of up to $26,500,000 based on a multiple of incremental net sales, which is payable in cash or at the Company’s discretion, up to 35% in Company common stock (up to an additional 2,863,948 shares), and additional consideration of $562,000. Differences in the contingent consideration recognized (including changes in fair value estimated at each reporting date) and the final amounts paid will be recorded in future Company results of operations.

Acquisition of BioD, LLC (Det40

Acquisition of BioD, LLC (Details 1) - BioD,LLC [Member] - USD ($)	9 Months Ended
	Sep. 30, 2016	Aug. 05, 2016
Total acquired identifiable intangible assets	$ 19,000,000	$ 19,000,000
Customer Relationships [Member]
Estimated Useful Life	5 years
Total acquired identifiable intangible assets	$ 10,000,000
Developed Technology Rights [Member]
Estimated Useful Life	10 years
Total acquired identifiable intangible assets	$ 6,000,000
Trademarks and Trade Names [Member]
Estimated Useful Life	10 years
Total acquired identifiable intangible assets	$ 2,000,000
Noncompete Agreements [Member]
Estimated Useful Life	3 years
Total acquired identifiable intangible assets	$ 1,000,000

Acquisition of BioD, LLC (Det41

Acquisition of BioD, LLC (Details 2) - BioD,LLC [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net sales	$ 23,776,960	$ 22,131,402	$ 69,048,342	$ 63,074,631
Net loss from continuing operations	$ (1,982,531)	$ (4,653,899)	$ (2,507,632)	$ (17,044,443)
Net loss from continuing operations per common share: basic and diluted	$ (0.07)	$ (0.17)	$ (0.09)	$ (0.63)
Weighted average number of shares: basic and diluted	27,826,807	27,327,813	27,554,311	27,228,578

Acquisition of BioD, LLC (Det42

Acquisition of BioD, LLC (Details Textual) - USD ($)		Aug. 05, 2016		Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	[1]	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs					$ 2,734,653	$ 0		$ 2,892,713	$ 0	[1]
Amortization of Intangible Assets								2,636,176	2,238,194
Operating Income (Loss), Total					(5,799,005)	$ (5,053,674)		(10,923,558)	$ (17,695,973)	[1]
Operating Income (Loss) [Member]
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs								2,892,713
BioD,LLC [Member]
Business Acquisition [Line Items]
Business Combination, Regulatory Milestone Payments								$ 29,699,691
Pro forma net sales, Percentage				35.00%				13.00%	12.00%
Business Combination Consideration Transferred Equity Interests Issued And Issuable, Shares				2,863,948
Payments to Acquire Businesses, Gross	[2]	$ 13,897,112
Net assets acquired		$ 77,706,554		$ 29,699,691
Business Combination Additional Consideration				$ 562,000	562,000			$ 562,000
Business Combination, Targeted Milestone Revenue in year One								26,500,000
Business Combination, Targeted Milestone Revenue in year Two								26,500,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		1,751,183
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	[2]	$ 9,197,875
Business Combination, Consideration Transferred, Liabilities Incurred		56,761,691
Business Acquisition, Expected Cost		3,107,535
Escrow Deposits Held For Working Capital Adjustments		2,000,000
Escrow Deposits Held For Collection Of Accounts Receivables		1,178,846
Escrow Deposit Disbursements Related To Working Capital Adjustments								440,054
Royalty Expense		$ 211,429						199,395
Incremental Common Shares Attributable to Dilutive Effect of Accelerated Share Repurchase Agreements		229,919
Revenues					3,985,643			3,985,643
Operating Income (Loss), Total					3,641,513			3,641,513
Business Combination, Consideration Transferred, Other		$ 903,408	[3]		370,000			370,000
BioD,LLC [Member] | Pro Forma [Member]
Business Acquisition [Line Items]
Amortization of Intangible Assets								1,866,667	$ 2,400,000
BioD,LLC [Member] | Operating Income (Loss) [Member]
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs					$ 2,892,713			$ 2,892,713
[1]	Reclassified for discontinued operations. See note 2.
[2]	Initial consideration includes $2,000,000 held in escrow to secure BioD payment obligations for working capital adjustments and any indemnification claims and $1,178,846 held in escrow pending the collection of two separate classes of accounts receivable. Amounts equal to the collected receivables through August 5, 2017 will be released to the sellers from the accounts receivable escrows with the remainder returned to the Company by September 4, 2017. In September 2016, the Company received $440,054 for working capital adjustments from these reserves.
[3]	Reflects settlement of pre-existing relationship between the Company and BioD.

Restructuring and Other Charg43

Restructuring and Other Charges (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Balance, January 1, 2016	$ 2,079,037
Charges during period	0
Payments during period	(1,322,910)
Balance, September 30, 2016	756,127
Less current portion	(609,396)
Long term portion	146,731
Chief Executive Officer [Member]
Balance, January 1, 2016	1,252,105
Charges during period	0
Payments during period	(506,366)
Balance, September 30, 2016	745,739
Less current portion	(599,008)
Long term portion	146,731
Other Employees [Member]
Balance, January 1, 2016	826,932
Charges during period	0
Payments during period	(816,544)
Balance, September 30, 2016	10,388
Less current portion	(10,388)
Long term portion	$ 0

Restructuring and Other Charg44

Restructuring and Other Charges (Details Textual)	12 Months Ended
	Dec. 31, 2015
Restructuring and Related Cost, Number of Positions Eliminated	39

Cash and Cash Equivalents and45

Cash and Cash Equivalents and Investments (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015		Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash	$ 20,974,166	$ 10,784,522
Cash equivalents	5,000,000	5,029,683
Cash and cash equivalents	25,974,166	15,814,205	[1]	$ 14,431,513	$ 19,396,845
Investments in debt securities	15,000,000	25,003,990
Investment in equity securities	15,426,148	16,110,178				$ 8,483,693
Total investments	30,426,148	41,114,168
Total cash and cash equivalents and investments	$ 56,400,314	$ 56,928,373
[1]	Reclassified for discontinued operations. See note 2.

Cash and Cash Equivalents and46

Cash and Cash Equivalents and Investments (Details 1) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Cash and cash equivalents	$ 25,974,166	$ 15,814,205
Total investments	30,426,148	41,114,168
Total	56,400,314	56,928,373
Debt Securities [Member]
Total investments	15,000,000	25,003,990
Equity Securities [Member]
Total investments	15,426,148	16,110,178
Quoted prices in active markets (Level 1) [Member]
Cash and cash equivalents	25,974,166	15,814,205
Total investments	30,426,148	41,114,168
Total	56,400,314	56,928,373
Quoted prices in active markets (Level 1) [Member] | Debt Securities [Member]
Total investments	15,000,000	25,003,990
Quoted prices in active markets (Level 1) [Member] | Equity Securities [Member]
Total investments	15,426,148	16,110,178
Significant other observable inputs (Level 2) [Member]
Cash and cash equivalents	0	0
Total investments	0	0
Total	0	0
Significant other observable inputs (Level 2) [Member] | Debt Securities [Member]
Total investments	0	0
Significant other observable inputs (Level 2) [Member] | Equity Securities [Member]
Total investments	0	0
Significant unobservable inputs (Level 3) [Member]
Cash and cash equivalents	0	0
Total investments	0	0
Total	0	0
Significant unobservable inputs (Level 3) [Member] | Debt Securities [Member]
Total investments	0	0
Significant unobservable inputs (Level 3) [Member] | Equity Securities [Member]
Total investments	$ 0	$ 0

Cash and Cash Equivalents and47

Cash and Cash Equivalents and Investments (Details Textual) - USD ($)	1 Months Ended
	Jun. 30, 2016	May 31, 2016	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity securities			1,877,277		2,802,277	2,802,277
Ownership percentage			5.00%
Available-for-sale Equity Securities, Amortized Cost Basis					$ 8,483,693	$ 8,483,693
Available-for-sale Securities, Equity Securities			$ 15,426,148	$ 16,110,178		$ 8,483,693
Common Stock, Shares, Outstanding			28,269,225	25,876,870
Gain (Loss) on Sale of Equity Investments	$ 4,740,136
Comvita stock [Member]
Equity Method Investments, Number of Shares Sold		925,000
Equity Method Investment, Amount Sold		$ 7,594,158
Common Stock, Shares, Outstanding			9,796,477

Inventories (Details)

Inventories (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Finished goods and available tissue for distribution	$ 8,302,804	$ 11,039,877
Goods and tissue in process	974,061	346,233
Packaging materials	1,489,483	1,152,993
Raw materials	3,626,825	3,811,910
Total inventories	$ 14,393,173	$ 16,351,013	[1]
[1]	Reclassified for discontinued operations. See note 2.

Notes Receivable (Details)

Notes Receivable (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes Receivable, Gross	$ 3,025,556	$ 0
Less current portion	938,677	0	[1]
Notes Receivable, Net	2,086,879	0	[1]
Interest Bearing Note Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes Receivable, Gross	2,700,000	0
Non- Interest Bearing Note Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes Receivable, Gross	$ 325,556	$ 0
[1]	Reclassified for discontinued operations. See note 2.

Notes Receivable (Details Textu

Notes Receivable (Details Textual)	Sep. 30, 2016USD ($)
Interest Bearing Note Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Accounts, Notes, Loans and Financing Receivable, Net, Current	$ 87,121
Non- Interest Bearing Note Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts, Notes, Loans and Financing Receivable, Net, Current	$ 10,556

Accrued Expenses and Other Li51

Accrued Expenses and Other Liabilities (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Accrued compensation and related taxes	$ 3,964,908	$ 2,298,080
Liabilities related to restructuring (Note 4)	756,127	2,079,037
Accrued sales incentives and other fees	574,620	385,573
Accrued royalties	482,025	510,901
Other	2,914,373	2,038,478
Total accrued expenses and other liabilities	8,692,053	7,312,069
Less current portion	(8,193,998)	(6,297,691)	[1]
Long term liabilities	$ 498,055	$ 1,014,378
[1]	Reclassified for discontinued operations. See note 2.

Stockholders' Equity (Details)

Stockholders' Equity (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Weighted Average Assumptions Used In Estimation Of Fair Value Of Option Awards [Line Items]
Risk-free interest rate	1.34%	1.85%	1.41%	1.61%
Volatility factor	43.80%	45.40%	43.90%	45.70%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected option life (years)	3 years 8 months 8 days	6 years 3 months	5 years 1 month 6 days	5 years 8 months 12 days

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1)	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Options
Outstanding Begining | shares	2,301,760
Granted | shares	813,660
Forfeited | shares	(130,862)
Exercised | shares	(7,475)
Expired | shares	(269,081)
Outstanding Ending | shares	2,708,002
Expected to vest - September 30, 2016 | shares	2,680,922
Exercisable at September 30, 2016 | shares	1,967,556
Weighted Average Exercise Price
Outstanding Begining | $ / shares	$ 9.04
Granted | $ / shares	3.86
Forfeited | $ / shares	5.87
Exercised | $ / shares	3.23
Expired | $ / shares	9.26
Outstanding Ending | $ / shares	7.63
Expected to vest - September 30, 2016 | $ / shares	7.63
Exercisable at September 30, 2016 | $ / shares	$ 8.42

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - Employee Stock Option [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 115,167	$ 565,334	$ 890,061	$ 2,043,765
Discontinued operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	(28,333)	23,258	(7,940)	106,238
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	26,406	23,740	87,170	109,047
Selling, general and administrative expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 117,094	$ 518,336	$ 810,831	$ 1,828,480

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3)	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Number of Units
Unvested - January 1, 2016 | shares	152,750
Granted | shares	301,800
Vested | shares	(90,450)
Cancelled | shares	(21,050)
Unvested - September 30, 2016 | shares	343,050
Weighted Average Fair Value
Unvested - January 1, 2016 | $ / shares	$ 8.59
Granted | $ / shares	4.63
Vested | $ / shares	7.5
Cancelled | $ / shares	7
Unvested - September 30, 2016 | $ / shares	$ 5.49

Stockholders' Equity (Details 4

Stockholders' Equity (Details 4)	Sep. 30, 2016shares
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	4,899,947
Restricted share units outstanding [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	343,050
Common stock options outstanding [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	2,708,002
Convertible preferred stock [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	73,332
Additional stock issuable related to conversion of preferred stock [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	49,782
Common stock equivalents available for grant [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	1,725,781

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Aug. 05, 2016	Sep. 30, 2016	May 31, 2016	May 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Stockholders Equity [Line Items]
Convertible Preferred Stock Additional Shares		49,782			49,782		49,782
Preferred Stock, Shares Outstanding		73,332			73,332		73,332		73,332
Convertible Preferred Stock, Shares Issued upon Conversion		123,114			123,114		123,114
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period							90,450
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							10 years
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate							1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							813,660
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 12,300
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost							$ 49,035
Shares Paid for Tax Withholding for Share Based Compensation							5,576
Shares withheld for minimum payroll taxes							$ 18,010
Common Stock, Capital Shares Reserved for Future Issuance		4,899,947			4,899,947		4,899,947
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate					0.00%	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							7,475
Common Stock, Shares Authorized		50,000,000			50,000,000		50,000,000		50,000,000
Stock Issued During Period, Shares, New Issues	551,665
Payments of Stock Issuance Costs	$ 66,433
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period							301,800
Warrant [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period							50,000
Private Placement [Member]
Stockholders Equity [Line Items]
Stock Issued During Period, Value, New Issues	$ 2,233,567
Common Stock [Member]
Stockholders Equity [Line Items]
Stock Issued During Period, Shares, Period Increase (Decrease)							2,392,355
Stock Issued During Period, Shares, Restricted Stock Award, Gross							84,874
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period							90,450
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							1,751,183
Selling, General and Administrative Expenses [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost							$ 48,733	$ 70,670
Service based options [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							611,260
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 1.60
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 1,034,531			$ 1,034,531		$ 1,034,531
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							2 years
Employee Stock Option [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value							$ 5,755
Allocated Share-based Compensation Expense					$ 115,167	$ 565,334	$ 890,061	2,043,765
Common Stock, Capital Shares Reserved for Future Issuance		1,725,781			1,725,781		1,725,781
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							4,633
Common Stock, Shares Authorized		6,000,000			6,000,000		6,000,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options, Beginning Balance		2,708,002			2,708,002		2,708,002
Employee Stock Option [Member] | Director [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			30,000	15,000
Employee Stock Option [Member] | Selling, General and Administrative Expenses [Member]
Stockholders Equity [Line Items]
Allocated Share-based Compensation Expense					$ 117,094	518,336	$ 810,831	1,828,480
Performance Shares [Member]
Stockholders Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							202,400
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 158,868			158,868		$ 158,868
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							1 year 7 months 6 days
Restricted Stock Units (RSUs) [Member]
Stockholders Equity [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 1,213,469			$ 1,213,469		$ 1,213,469
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							1 year 8 months 12 days
Common Stock, Capital Shares Reserved for Future Issuance		343,050			343,050		343,050
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total							343,050
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested		$ 1,602,044			$ 1,602,044		$ 1,602,044
Restricted Stock Units (RSUs) [Member] | Selling, General and Administrative Expenses [Member]
Stockholders Equity [Line Items]
Allocated Share-based Compensation Expense					$ 257,833	$ 652,286	$ 807,589	$ 1,971,993
Series R [Member]
Stockholders Equity [Line Items]
Class of warrant or right, Warrants forfeited							1,705,330

Accumulated Other Comprehensi58

Accumulated Other Comprehensive Income (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Balance at January 1, 2016	$ 5,272,908
Other comprehensive income before reclassification	4,908,289
Amounts reclassified from accumulated other comprehensive income	(2,975,813)	$ 0
Balance at June 30, 2016	7,205,384
Foreign Currency Translation Adjustments [Member]
Balance at January 1, 2016	555,938
Other comprehensive income before reclassification	575,471
Amounts reclassified from accumulated other comprehensive income	0
Balance at June 30, 2016	1,131,409
Unrealized Gain on Equity Securities [Member]
Balance at January 1, 2016	4,716,970
Other comprehensive income before reclassification	4,332,818
Amounts reclassified from accumulated other comprehensive income	(2,975,813)
Balance at June 30, 2016	$ 6,073,975

Accumulated Other Comprehensi59

Accumulated Other Comprehensive Income (Details 1) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Reclassification from AOCI, Current Period, Net of Tax [Abstract]
Income tax provision	$ 1,782,823	$ 0
Amounts reclassified from accumulated other comprehensive income	(2,975,813)	$ 0
Other Income [Member]
Reclassification from AOCI, Current Period, Net of Tax [Abstract]
Realized gain on equity securities	(4,758,636)
Income Tax Provision [Member]
Reclassification from AOCI, Current Period, Net of Tax [Abstract]
Income tax provision	$ 1,782,823

Operating Segments (Details)

Operating Segments (Details) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2016		Sep. 30, 2015		Sep. 30, 2016		Sep. 30, 2015
Segment Reporting Information [Line Items]
Net sales	$ 21,809,526		$ 17,787,527	[1]	$ 55,525,732		$ 51,371,639	[1]
Gross profit	10,706,462		7,295,595	[1]	24,771,503		21,061,176	[1]
Direct expense	(13,169,775)	[2]	(8,723,791)		(26,471,153)	[2]	(27,464,208)
Segment contribution	(2,463,313)		(1,428,196)		(1,699,650)		(6,403,032)
Indirect expenses, net	(2,109,986)		(3,245,845)		(3,257,218)		(10,697,366)
Net loss from continuing operations	(4,573,299)		(4,674,041)	[1]	(4,956,868)		(17,100,398)	[1]
Advanced Wound Care [Member]
Segment Reporting Information [Line Items]
Net sales	15,789,683		11,348,591		37,364,124		31,411,631
Gross profit	9,419,831		5,496,935		20,655,523		15,260,095
Direct expense	(12,744,522)	[2]	(7,957,641)		(24,987,258)	[2]	(25,173,533)
Segment contribution	(3,324,691)		(2,460,706)		(4,331,735)		(9,913,438)
Traditional Wound Care [Member]
Segment Reporting Information [Line Items]
Net sales	6,019,843		6,438,936		18,161,608		19,960,008
Gross profit	1,286,631		1,798,660		4,115,980		5,801,081
Direct expense	(425,253)	[2]	(766,150)		(1,483,895)	[2]	(2,290,675)
Segment contribution	861,378		1,032,510		2,632,085		3,510,406
Other [Member]
Segment Reporting Information [Line Items]
Net sales	0		0		0		0
Gross profit	0		0		0		0
Direct expense	0	[2]	0		0	[2]	0
Segment contribution	0		0		0		0
Indirect expenses, net	$ (2,109,986)		$ (3,245,845)		$ (3,257,218)		$ (10,697,366)
[1]	Reclassified for discontinued operations. See note 2.
[2]	The advanced wound care segment includes acquisition related costs of $2,734,653 and $2,892,713 and changes in fair value of contingent consideration of $370,000 and $370,000 for the three and nine months ended September 30, 2016, respectively.

Operating Segments (Details 1)

Operating Segments (Details 1) - Sales Revenue, Net [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration Risk, Percentage	83.00%	84.00%	80.00%	84.00%
Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration Risk, Percentage	11.00%	11.00%	13.00%	11.00%
Rest of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration Risk, Percentage	6.00%	5.00%	7.00%	5.00%

Operating Segments (Details Tex

Operating Segments (Details Textual) - USD ($)	Aug. 05, 2016	[2]	Sep. 30, 2016	Sep. 30, 2015		Sep. 30, 2016	Sep. 30, 2015
Concentration Risk [Line Items]
Business Combination, Acquisition Related Costs			$ 2,734,653	$ 0	[1]	$ 2,892,713	$ 0	[1]
BioD,LLC [Member]
Concentration Risk [Line Items]
Business Combination, Consideration Transferred, Other	$ 903,408		$ 370,000			$ 370,000
Sales Revenue, Net [Member] | CANADA
Concentration Risk [Line Items]
Concentration Risk, Percentage			11.00%	11.00%		13.00%	11.00%
[1]	Reclassified for discontinued operations. See note 2.
[2]	Reflects settlement of pre-existing relationship between the Company and BioD.

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015		Sep. 30, 2016	Sep. 30, 2015
Income Tax Expense Benefit [Line Items]
Current tax expense	$ (31,315)	$ (170,082)		$ (260,190)	$ (252,735)
Deferred tax benefit	1,487,592	1,221,974		648,413	1,007,843
Income tax benefit (expense)	$ 1,456,277	$ 1,051,892	[1]	$ 1,394,120	$ 755,108	[1]
Effective tax rate	(24.20%)	(18.40%)		(22.00%)	(4.20%)
[1]	Reclassified for discontinued operations. See note 2.

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Jul. 31, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Commitments and Contingencies [Line Items]
Inventory, Finished Goods, Net of Reserves		$ 8,302,804		$ 11,039,877
Share-based Compensation, Stock	$ 49,035
Dividends, Share-based Compensation, Cash	434,634
Payment Terms From Distributor		0.90%
Selling, General and Administrative Expenses [Member]
Commitments and Contingencies [Line Items]
Compenastion Expense	$ 483,669
Supply Commitment [Member]
Commitments and Contingencies [Line Items]
Inventory, Finished Goods, Net of Reserves		$ 2,050,000
Comvita Agreement [Member]
Commitments and Contingencies [Line Items]
Related Party Transaction, Purchases from Related Party		1,879,332	$ 2,626,705
Royalty Expense		1,136,498	$ 1,086,392
Due to Related Parties		$ 973,156		$ 506,795